News

Mechanism of action of dinaciclib reveals potential synergistic activity with certain anti-myeloma treatments

Researchers at Virginia Commonwealth University Massey Cancer Centre, USA, have identified the mechanism responsible for the anti-tumour activity of the cyclin-dependent kinase inhibitor dinaciclib and suggest that it could improve the effectiveness of certain anti-myeloma treatments. The results of the preclinical study, published in Molecular Cancer Therapeutics, showed that dinaciclib disrupted the unfolded protein response…

Details

Calithera initiates Phase I trial of CB-839 for relapsed and/or refractory myeloma patients

Calithera Biosciences, the American biopharmaceutical company, has announced the start of a Phase I trial of its proprietary drug CB-839 for the treatment of relapsed and/or refractory myeloma. CB-839 is a first-in-class orally bioavailable glutaminase inhibitor that interferes with tumour metabolism and blocks cancer cell growth and survival. In preclinical studies, it has been shown…

Details

VelcadeĀ® induction approved for use in NHS Scotland

The Scottish Medicines Consortium (SMC) has accepted the use of Velcade as part of induction treatment with dexamethasone, or with dexamethasone and thalidomide, for newly diagnosed myeloma patients prior to high-dose therapy and stem cell transplantation. Scotland, therefore, becomes the first part of the UK to approve Velcade in the induction setting. The National Institute…

Details

Study uncovers genetic diversity within tumours

A recent study, considered to be the most comprehensive of its type to date, has revealed that the genetic landscape of myeloma may be more complex than previously thought. Published in the latest issue of Cancer Cell, researchers from The Broad Institute, Cambridge, MA, USA performed massively parallel sequencing of paired tumour/normal samples from over…

Details

Updated IMWG guidelines for myeloma patients not eligible for high-dose therapy and stem cell transplantation

The International Myeloma Working Group has recently published a consensus statement updating recommendations for the treatment and management of myeloma patients not eligible for high-dose therapy and stem cell transplantation. It recommends that clinicians should consider age, comorbidities and a geriatric assessment to determine whether patients are fit or unfit for transplant, and that drug…

Details

Study supports the use of whole-body diffusion-weighted MRI for measuring response to treatment in myeloma

Researchers from The Institute of Cancer Research (ICR) have shown that whole-body diffusion-weighted (DW) magnetic resonance imaging (MRI) may be a useful method for assessing treatment response in myeloma patients. In the study, 26 patients completed whole-body DW imaging before and after treatment. Bone marrow manifestations were evaluated by quantitative analysis using apparent diffusion coefficient…

Details